CAM 20470

Genetic Testing for Lipoprotein A Variant as a Decision Aid for Aspirin Treatment and/or CVD Risk Assessment

Category:Laboratory   Last Reviewed:January 2021
Department(s):Medical Affairs   Next Review:January 2022
Original Date:May 2013    

Description
Lipoprotein(a) (Lp(a)) is a type of low-density lipoprotein (LDL) that consists of a cholesterol bearing LDL – like particle (apolipoprotein B-100) bound to the plasminogen-like glycoprotein apolipoprotein(a) (apo(a)) (Lu et al., 2015; Schmidt, Noureen, Kronenberg, & Utermann, 2016) and has been associated with increased risk for cardiovascular disease (CVD) (Tsimikas et al., 2018). Genetic variants of the Lp(a) gene, LPA, (rs3798220 and rs10455872) have been significantly associated with Lp(a) levels (Lu et al., 2015) and could serve as indicators of CVD risk (Lee et al., 2017). The genetic variant rs3798220 was found to have a higher risk for thrombosis and therefore may derive more benefit from the anti-thrombotic properties of aspirin (Chasman et al., 2009). As a result, testing for the rs3798220 variant has been proposed as a method of stratifying benefit from aspirin treatment (Shiffman, Slawsky, Fusfeld, Devlin, & Goss, 2012).

This policy only addresses the detection of specific genetic variants of Lp(a) as a decision aid for aspirin therapy or CVD risk.

Background  
LIPOPROTEIN(A)
Extensive epidemiologic evidence has determined that lipoprotein(a) (LPA) blood level is an independent risk factor for cardiovascular disease. The overall risk associated with LPA appears to be modest, and the degree of risk may be mediated by other factors such as low-density lipoprotein (LDL) levels and/or hormonal status.

Over time, a person’s LPA levels remain relatively stable; however, levels have been known to vary up to 1,000-fold between different people, and this is most likely due to genetics. A single-nucleotide variant in the LPA gene, LPA rs3798220, has been associated with both elevated LPA levels and an increased risk of cardiovascular disease. This variant substitutes methionine for isoleucine at amino acid position 4399 and is also called I4399M. Mendelian randomization studies have supported the hypothesis that this genetic variant, and the subsequent increase in LPA levels, are causative of cardiovascular disease.

Aspirin is a well-established treatment for patients with known coronary artery disease. It also is prescribed as primary prevention for some patients who are at increased risk of coronary artery disease. Current recommendations for primary prevention consider the future risk of cardiovascular events weighed against the bleeding risk of aspirin. The U.S. Preventive Services Task Force 2009 Guidelines recommended aspirin for men between the ages of 45 and 79 years when the benefit in reducing myocardial infarction exceeds the risk of bleeding, particularly gastrointestinal hemorrhage; and for women between the ages of 55 and 79 years when the benefit in reducing stroke exceeds the risk of gastrointestinal bleeding.1 Given such guidelines that recommend individualizing the risk-benefit ratio of aspirin therapy, additional tools that would aid in better defining the benefits of aspirin, and/or the risk of bleeding, have potential utility for clinicians who are making decisions about aspirin therapy.

LPA Aspirin Genotype is a commercially available genetic test (Berkeley HeartLab, a Quest Diagnostics service) that detects the presence of the rs3798220 allele. Patients with a positive test for rs3798220 have a higher risk for thrombosis and therefore may derive more benefit from the antithrombotic properties of aspirin. It has been proposed that the additional information obtained from the LPA Aspirin Check® test may aid physicians in better estimating the benefit/risk of aspirin therapy and therefore may aid in deciding whether to prescribe aspirin for individual patients. 

Regulatory Status
The LPA-Aspirin Check® test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Thus, genotyping is offered as a laboratory-developed test. Clinical laboratories may develop and validate tests in-house (“home-brew”) and market them as a laboratory service. Such tests must meet general regulatory standards of the Clinical Laboratory Improvement Act (CLIA).The laboratory offering the service must be licensed by CLIA for high-complexity testing. Berkeley HeartLab is a CLIA-certified laboratory.

Related Policies
20432 Measurement of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in the Assessment of Cardiovascular Risk

Policy

  1. The use of genetic testing for the rs3798220 allele (including proprietary testing such as LPA-Aspirin Check® and Cardio IQ® LPA Aspirin Genotype) is considered investigatonal and /or unproven and therefore considered NOT MEDICALLY NECESSARY in patients who are being CONSIDERED for treatment with aspirin to reduce risk of cardiovascular events.
  2. The use of genotyping of lipoprotein a (Lp(a)), including genetic testing for the rs3798220 single nucleotide polymorphism (SNP), the rs10455872 SNP, and/or the rs9457951 SNP, is considered investigational and /or unproven and therefore considered NOT MEDICALLY NECESSARY in all situations.  

Policy Guidelines
GENETIC COUNSELING
Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

CODING
There is no specific CPT code for this test. The unlisted molecular pathology code 81479 would be reported. 

Rationale
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality; with over 11.5% of American adults (27.6 million) diagnosed with heart disease, it claims more lives each year than cancer and chronic lower respiratory disease combined. While progression of CVD is multifactorial, pathophysiological, and epidemiological, genetic studies have provided substantial evidence that Lp(a) is a causal risk factor contributing to CVD. Lp(a) is also elevated in heterozygous familial hypercholesterolemia, further increasing atherosclerotic CVD risk in that disease setting. The physiological role of Lp(a) is to bind and transport proinflammatory oxidized phospholipids in plasma, but its key relation to CVD has been the involvement in atherothrombosis, from the formation of an atherosclerotic plaque through inducing expression of inflammatory mediators and increasing foam formation, to thrombosis following plaque rupture. Independent of any other risk factors, Lp(a) was positively associated with increased risk of myocardial infarctions (MI) as well.

Since first described by Berg (1963) as a genetic trait increased in patients with coronary heart disease, Lp(a) has been characterized as a type of LDL consisting of apolipoprotein B-100 covalently bound to apolipoprotein(a). The plasma level and size of Lp(a) are regulated through strict genetic control by the apo(a) gene (LPA) on chromosome 6q26-27 with some influence from the APOE locus. The LPA gene is highly polymorphic based on the number of kringle (five cysteine-rich domains) IV (KIV) repeats, therefore encoding >40 apo(a) isoforms of varying molecular weights.

As it is genetically controlled, the concentration of Lp(a) is generally stable; correlates inversely with molecular size (smaller size correlating with higher serum levels); and is minimally influenced by age, weight and diet. Genetic variants of apo(a) have been found to have predictive value in coronary heart disease (CHD). Beyond CHD, genetically lowered Lp(a) is also associated with a lower risk of peripheral vascular disease, stroke, heart failure, and aortic stenosis.

The prevalence and association of these genetic variants with apo(a) size and Lp(a) levels are highly variable and ethnicity-specific. Out of 118 single nucleotide polymorphisms (SNPs) identified, rs3798220 is most prevalent in Hispanics (42.38%), rs10455872 in Whites (14.27%), and rs9457951 in Blacks (32.92%). In Hispanics, the rs3798220 variant was associated with large isoforms and lower Lp(a) levels, but in Whites, this variant was associated with very small isoforms and higher Lp(a) levels. In a separate study that analyzed the relationship between Lp(a) concentration and risk of MI, Paré et al. (2019) found that the clinical use of Lp(a) concentrations for interventions to reduce MI risk would be useful among diverse populations, especially South Asians and Latin Americans, but not Africans or Arabs since there was an insignificant association between high Lp(a) concentration and MI risk in these populations.

Although its biology and pathophysiology is still incompletely understood, Lp(a) is recognized as both atherogenic and thrombogenic, possibly due to its structural homology with plasminogen. It is thought that Lp(a) could compete with plasminogen for fibrin binding, ultimately resulting in impaired fibrinolysis.

A specific SNP in the LPA gene (rs3798220) results in an isoleucine-to-methionine substitution within the inactive protease domain, triggering a smaller number of kringle IV repeats, elevated Lp(a) levels, and a greater risk for CVD. This amino acid substitution (I4399M) has been studied for its effects on coagulation, fibrinolysis, and overall fibrin cloth structure.

Carriers of either the rs3798220 or rs10455872 variant were found to have no difference in plasminogen concentration or clot lysis time. The I4399M variant was found to accelerate the coagulation of plasma clots in vitro, therefore suggesting that those with this variant may benefit from the anti-thrombotic properties of aspirin. Further, a difference in phenotypic expression between different ethnic groups has been found. Among non-Caucasians, carriers of the rs3798220 variant had increased clot permeability and shorter lysis time, whereas among Caucasians, the trend was for decreased permeability and longer lysis time. A correlation was identified between the I4399M variant and both elevated plasma Lp(a) levels and an increased risk of CHD; carriers of this variant in population studies also showed an increased benefit of aspirin therapy.

Clinical Validity and Utility
The additional information obtained from the testing for Lp(a) genotype may aid physicians in better estimating the benefit/risk of aspirin therapy and therefore aid in deciding whether to prescribe aspirin for individual patients. LPA genotyping in the context of the aspirin use guidelines for primary prevention of CVD was found to be potentially cost-effective. However, traditional plasma-based hemostasis-thrombosis laboratory testing may be more effective at managing venous thrombotic disease than a single DNA variant with a small effect size and no established mechanism linking aspirin with Lp(a).

An analysis of the Women’s Health Study comprised of a randomized trial of low-dose aspirin found that rs3798220 was associated with elevated Lp(a) and doubled CVD risk that could be attenuated by aspirin; carriers appeared to benefit more from aspirin than non-carriers.

Ozkan, Ozcelik, Yildiz, and Budak (2019) have recently shown that Lp(a) gene polymorphisms play a role in the development of calcific aortic stenosis or calcific aortic valve disease (CAVD); blood samples were taken from 75 patients previously diagnosed with CAVD and 77 healthy controls. Results showed that “A significant association among smoking, elevated LDL level and creatinine, low albumin levels, Lp(a) level, rs10455872, and rs3798220 polymorphisms may be considered genetic risk factors for the development of calcific aortic stenosis” (Ozkan et al., 2019). However, even with a strong statistically significant relationship between the Lp(a) gene polymorphisms (rs10455872, and rs3798220) and CAVD, this study contained a relatively small sample size, suggesting that more research needs to be completed to validate these results. This research has been corroborated by Pechlivanis et al., who demonstrated that the rs10455872 SNP has a statistically significant association with coronary artery calcification, a predictor of coronary artery disease.

A large-scale study with 44,703 participants of European descent was completed, and a relationship was identified between two Lp(a) variants (rs10455872 and rs3798220) and aortic stenosis (AS) development. While a relationship between both of these Lp(a) variants has already been established in regards to circulating Lp(a) plasma levels and a high Lp(a) risk score, these data seem to confirm the association between these Lp(a) variants and valvular or cardiac disease events. Final results from this study showed that the participants with these two high-risk alleles had two times or more a chance of developing AS; however, it must be noted that participants with AS were on average older than the controls, meaning that some controls could still develop AS.

Mu-Han-Ha-Li et al. (2018) conducted a study with 1,863 Chinese patients with very high CVD risk (as identified on coronary angiography) to analyze the connection between Lp(a) levels and the risks of CVD and diabetes. Researchers concluded that a high number of LPA KIV type 2 repeats, and therefore lower serum Lp(a) levels, is associated with an increased risk of type 2 diabetes in a Chinese population with high CVD risk, suggesting that a large Lp(a) isoform size, and thus low Lp(a) concentration, can have a causal effect on type 2 diabetes. With this novel association, it becomes essential for genetic testing of LPA gene variants to not only follow up on CVD risk to assess benefit from aspirin therapy, but for the possible latter development of comorbidities like type 2 diabetes.

Additional researchers have identified a potential relationship between Lp(a) SNPs and a high inflammatory response that may result in an increased CVD risk in pregnant women; Tuten et al. (2019) analyzed data from 200 pregnant Turkish women, evaluating 14 different Lp(a) SNPs. Results found that two of the Lp(a) SNPs, rs9355296 and rs3798220, were identified as risk factors for preeclampsia, and that rs9355296 carriers reported higher vascular inflammatory rates. These results suggest that specific Lp(a) variants may possibly be used as biomarkers for future cardiovascular events and inflammation.

Moreover, Wang and Zhang (2019) showed that high Lp(a) levels are associated with adverse clinicopathological features in prostate cancer patients. Patients with a prostate specific antigen (PSA) level ≥ 100 ng/ml had significantly higher Lp(a) levels; this was believed to be a result of compensatory mechanisms to chronic inflammation caused by tumor aggressiveness and invasion. The researchers also found that the percentage of metastases increased with elevation in Lp(a) level, while body mass index (BMI) decreased with the Lp(a) elevation. The increased metastasis in the setting of high Lp(a) levels was believed to be due to facilitated formations of fibrin networks (apo(a), a part of Lp(a), has structural homologues to kringle IV in plasminogen, which normally induces fibrinolysis) and thrombus formation that allowed for cancer cell adhesion. Genetic testing for Lp(a) may not only benefit CVD risk with aspirin therapy, but also implications with cancer development and treatment.

American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE)
The AACE/ACE published guidelines for the management of Dyslipidemia and Prevention of Cardiovascular Disease which state:

“Testing for lipoprotein(a) is therefore not generally recommended, although it may provide useful information to ascribe risk in Caucasians with ASCVD, those with an unexplained family history of early ASCVD, or those with unknown family history such as adopted individuals.”

Genetic screening for Lp(a) variants is not mentioned.

National Heart, Lung, and Blood Institute (NHLBI)
The NHLBI published Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis which endorsed the European Society of Cardiology/European Atherosclerosis Society, Canadian Cardiovascular Society, and National Lipid Association Guidelines while making additional specific recommendations to facilitate basic, mechanistic, preclinical, and clinical research on Lp(a).

Genetic screening for Lp(a) variants is not mentioned.

American College of Cardiology/American Heart Association
The ACC and AHA issued joint guidelines on the assessment of cardiovascular risk based on a systematic review conducted by an expert panel appointed by the National Heart, Lung, and Blood Institute. The panel noted that LPA was considered as a risk predictor, but its contribution to risk assessment “awaits further consideration at a later time.”

The ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents refer to elevated lipoprotein(a) as an comorbidity that increased ASCVD risk.

Genetic screening for Lp(a) variants is not mentioned.

The National Lipid Association (NLA)
The NLA considers Lp(a) to be an important clinical biomarker and risk factor for atherosclerotic cardiovascular disease. It is stated that a main obstacle towards the clinical use of Lp(a) is that measurements and various other targeted levels have not yet been standardized in the industry; for example, several of the available assays are reporting results in differing units, such as in mass instead of concentration. Based on current data, Wilson et al. (2019) has stated that Lp(a) testing in clinical practice is reasonable for select individuals with the qualifications listed below:  

  • Adults older than 20 years with a family history of premature atherosclerotic cardiovascular disease (ASCVD)
  • “Individuals with premature ASCVD (55y of age in men; 65y of age in women), particularly in the absence of traditional risk factors
  • Individuals with primary severe hypercholesterolemia (LDL-C ≥ 190 mg/dL) or suspected FH
  • Individuals at very-high-risk of ASCVD to better define those who are more likely to benefit from PCSK9 inhibitor therapy”

Wilson et al. (2019) also stated that Lp(a) testing may be reasonable in patients with: 

  • “Intermediate (7.5%–19.9%) 10-y ASCVD risk when the decision to use a statin is uncertain, to improve risk stratification in primary prevention
  • Borderline (5%–7.4%) 10-y ASCVD risk when the decision to use a statin is uncertain, to improve risk stratification in primary prevention
  • Less-than-anticipated LDL-C lowering, despite good adherence to LDL-C lowering therapy
  • A family history of elevated Lp(a)
  • Calcific valvular aortic stenosis
  • Recurrent or progressive ASCVD, despite optimal lipid-lowering therapy”

The NLA has previously published recommendations for the Patient-Centered Management of Dyslipidemia (Jacobson et al., 2015) which lists Lipoprotein (a) >50mg/dL as an additional risk  indicator that physicians could consider, partially in patients with moderate risk.

Genetic screening for Lp(a) variants is not mentioned in the NLA’s official guidelines.

The European Society for Cardiology (ESC) and European Atherosclerosis Society (EAS)
The ESC and EAS published Guidelines for the Management of Dyslipidemias which recommend: “Plasma Lp(a) is not recommended for risk screening in the general population; however, Lp(a) measurement should be systematically considered in people with high CVD risk or a strong family history of premature atherothrombotic disease. The risk is regarded as significant when Lp(a) is above the 80th percentile (50 mg/dL). Including Lp(a) in risk evaluation has been shown to give a correct reclassification and should be considered in patients on the borderline between high and moderate risk.”

Genetic screening for Lp(a) variants is not mentioned.

American Society for Clinical Pathology (ASCP)/Choosing Wisely
The American Society for Clinical Pathology (ASCP, 2016), as part of the Choosing Wisely Campaign, recommended that “a standard lipid profile includes total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. These lipids are carried within lipoprotein particles that are heterogeneous in size, density, charge, core lipid composition, specific apolipoproteins, and function. A variety of lipoprotein assays have been developed that subfractionate lipoprotein particles according to some of these properties, such as size, density, or charge. However, selection of these lipoprotein assays for improving assessment of risk of cardiovascular disease and guiding lipid-lowering therapies should be on an individualized basis for intermediate to high-risk patients only. They are not indicated for population based cardiovascular risk screening.”

Genetic screening for Lp(a) variants is not mentioned.

HEART UK Medical, Scientific, and Research Committee
HEART UK published guidelines for Lp(a) measurement in specific adult populations.

On genetic testing for Lp(a) levels, the guideline also noted, “Genetic testing for SNPs associated with serum Lp(a) levels is not currently advocated for in routine clinical practice”.

U.S. Preventive Services Task Force (USPSTF)
U.S. Preventive Services Task Force (USPSTF) guidelines from 2016 recommendation for aspirin do not mention Lp(a) or genetic screening for Lp(a).

References 

  1. Anderson, J. L., Knight, S., May, H. T., Horne, B. D., Bair, T. L., Huntinghouse, J. A., . . . Carlquist, J. F. (2013). Validation and quantification of genetic determinants of lipoprotein-a levels and predictive value for angiographic coronary artery disease. Am J Cardiol, 112(6), 799-804. doi:10.1016/j.amjcard.2013.05.009
  2. ASCP. (2016). Screening for cardiovascular disease | Choosing Wisely. Retrieved from http://www.choosingwisely.org/clinician-lists/american-society-clinical-pathology-expanded-lipid-panels-to-screen-for-cardiovascular-disease/
  3. Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., . . . Stroke Statistics, S. (2018). Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation, 137(12), e67-e492. doi:10.1161/CIR.0000000000000558
  4. Berg, K. (1963). A New Serum Type System in Man--the Lp System. Acta Pathol Microbiol Scand, 59, 369-382. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/14064818
  5. Berg, K., Dahlen, G., & Frick, M. H. (1974). Lp(a) lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease. Clin Genet, 6(3), 230-235. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/4372011
  6. Cairns, B. J., Coffey, S., Travis, R. C., Prendergast, B., Green, J., Engert, J. C., . . . Clarke, R. (2017). A Replicated, Genome-Wide Significant Association of Aortic Stenosis With a Genetic Variant for Lipoprotein(a): Meta-Analysis of Published and Novel Data. Circulation, 135(12), 1181-1183. doi:10.1161/CIRCULATIONAHA.116.026103
  7. Caplice, N. M., Panetta, C., Peterson, T. E., Kleppe, L. S., Mueske, C. S., Kostner, G. M., . . . Simari, R. D. (2001). Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood, 98(10), 2980-2987. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11698280
  8. Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., . . . Group, E. S. C. S. D. (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 37(39), 2999-3058. doi:10.1093/eurheartj/ehw272
  9. Cegla, J., Neely, R. D. G., France, M., Ferns, G., Byrne, C. D., Halcox, J., . . . Soran, H. (2019). HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis, 291, 62-70. doi:10.1016/j.atherosclerosis.2019.10.011
  10. Chasman, D. I., Shiffman, D., Zee, R. Y., Louie, J. Z., Luke, M. M., Rowland, C. M., . . . Ridker, P. M. (2009). Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis, 203(2), 371-376. doi:10.1016/j.atherosclerosis.2008.07.019
  11. Chen, H. Y., Dufresne, L., Burr, H., Ambikkumar, A., Yasui, N., Luk, K., . . . Thanassoulis, G. (2018). Association of LPA Variants With Aortic Stenosis: A Large-Scale Study Using Diagnostic and Procedural Codes From Electronic Health Records. JAMA Cardiol, 3(1), 18-23. doi:10.1001/jamacardio.2017.4266
  12. Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., . . . Consortium, P. (2009). Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med, 361(26), 2518-2528. doi:10.1056/NEJMoa0902604
  13. Emdin, C. A., Khera, A. V., Natarajan, P., Klarin, D., Won, H. H., Peloso, G. M., . . . Consortium, C. A. E. (2016). Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. J Am Coll Cardiol, 68(25), 2761-2772. doi:10.1016/j.jacc.2016.10.033
  14. Enkhmaa, B., Anuurad, E., & Berglund, L. (2016). Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res, 57(7), 1111-1125. doi:10.1194/jlr.R051904
  15. Erhart, G., Lamina, C., Lehtimaki, T., Marques-Vidal, P., Kahonen, M., Vollenweider, P., . . . Coassin, S. (2018). Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns. Arterioscler Thromb Vasc Biol, 38(5), 1230-1241. doi:10.1161/ATVBAHA.118.310865
  16. Fras, Z. (2020). Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities. Anatol J Cardiol, 23(2), 60-69. doi:10.14744/AnatolJCardiol.2019.56068
  17. Goff, D. C., Jr., Lloyd-Jones, D. M., Bennett, G., Coady, S., D'Agostino, R. B., Sr., Gibbons, R., . . . Wilson, P. W. (2014). 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 63(25 Pt B), 2935-2959. doi:10.1016/j.jacc.2013.11.005
  18. Grainger, D. J., Kirschenlohr, H. L., Metcalfe, J. C., Weissberg, P. L., Wade, D. P., & Lawn, R. M. (1993). Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science, 260(5114), 1655-1658. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8503012
  19. Guirguis-Blake, J. M., Evans, C. V., Senger, C. A., O'Connor, E. A., & Whitlock, E. P. (2016). Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med, 164(12), 804-813. doi:10.7326/m15-2113
  20. Hajjar, K. A., Gavish, D., Breslow, J. L., & Nachman, R. L. (1989). Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature, 339(6222), 303-305. doi:10.1038/339303a0
  21. ancock, M. A., Boffa, M. B., Marcovina, S. M., Nesheim, M. E., & Koschinsky, M. L. (2003). Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem, 278(26), 23260-23269. doi:10.1074/jbc.M302780200
  22. Helgadottir, A., Gretarsdottir, S., Thorleifsson, G., Holm, H., Patel, R. S., Gudnason, T., . . . Stefansson, K. (2012). Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol, 60(8), 722-729. doi:10.1016/j.jacc.2012.01.078
  23. Hervio, L., Durlach, V., Girard-Globa, A., & Angles-Cano, E. (1995). Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry, 34(41), 13353-13358. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/7577920
  24. Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., . . . Brown, W. V. (2015). National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol, 9(2), 129-169. doi:10.1016/j.jacl.2015.02.003
  25. Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., . . . Davidson, M. (2017). AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract, 23(Suppl 2), 1-87. doi:10.4158/ep171764.appgl
  26. Lee, S. R., Prasad, A., Choi, Y. S., Xing, C., Clopton, P., Witztum, J. L., & Tsimikas, S. (2017). LPA Gene, Ethnicity, and Cardiovascular Events. Circulation, 135(3), 251-263. doi:10.1161/CIRCULATIONAHA.116.024611
  27. Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., Jr., DePalma, S. M., . . . Smith, S. C., Jr. (2016). 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol, 68(1), 92-125. doi:10.1016/j.jacc.2016.03.519
  28. Lu, W., Cheng, Y. C., Chen, K., Wang, H., Gerhard, G. S., Still, C. D., . . . Fu, M. (2015). Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. Hum Mol Genet, 24(8), 2390-2400. doi:10.1093/hmg/ddu731
  29. Luke, M. M., Kane, J. P., Liu, D. M., Rowland, C. M., Shiffman, D., Cassano, J., . . . Ellis, S. G. (2007). A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol, 27(9), 2030-2036. doi:10.1161/ATVBAHA.107.141291
  30. Marcovina, S. M., Hobbs, H. H., & Albers, J. J. (1996). Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem, 42(3), 436-439. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8598109
  31. Marcovina, S. M., & Koschinsky, M. L. (2003). Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol, 14(4), 361-366. doi:10.1097/01.mol.0000083765.66245.9f
  32. McLean, J. W., Tomlinson, J. E., Kuang, W. J., Eaton, D. L., Chen, E. Y., Fless, G. M., . . . Lawn, R. M. (1987). cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature, 330(6144), 132-137. doi:10.1038/330132a0
  33. Moriarty, P. M., Varvel, S. A., Gordts, P. L., McConnell, J. P., & Tsimikas, S. (2017). Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients. Arterioscler Thromb Vasc Biol, 37(3), 580-588. doi:10.1161/ATVBAHA.116.308704
  34. Mu-Han-Ha-Li, D. L., Zhai, T. Y., Ling, Y., & Gao, X. (2018). LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk. J Lipid Res, 59(5), 884-891. doi:10.1194/jlr.P082792
  35. Nagalla, S., & Bray, P. F. (2016). Personalized medicine in thrombosis: back to the future. Blood, 127(22), 2665-2671. doi:10.1182/blood-2015-11-634832
  36. Nordestgaard, B. G., Chapman, M. J., Ray, K., Boren, J., Andreotti, F., Watts, G. F., . . . Tybjaerg-Hansen, A. (2010). Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 31(23), 2844-2853. doi:10.1093/eurheartj/ehq386
  37. Ozkan, U., Ozcelik, F., Yildiz, M., & Budak, M. (2019). Lipoprotein(a) Gene Polymorphism Increases a Risk Factor for Aortic Valve Calcification. J Cardiovasc Dev Dis, 6(3). doi:10.3390/jcdd6030031
  38. Paré, G., Çaku, A., McQueen, M., Anand Sonia, S., Enas, E., Clarke, R., . . . null, n. (2019). Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation, 139(12), 1472-1482. doi:10.1161/CIRCULATIONAHA.118.034311
  39. Pechlivanis, S., Mahabadi, A. A., Hoffmann, P., Nöthen, M. M., Broecker-Preuss, M., Erbel, R., . . . Jöckel, K. H. (2020). Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification. BMC Med Genet, 21(1), 62. doi:10.1186/s12881-020-01003-3
  40. Quest_Diagnostics. (2019). Cardio IQ® LPA Aspirin Genotype. Retrieved from https://testdirectory.questdiagnostics.com/test/test-detail/90553/cardio-iq-lpa-aspirin-genotype?cc=MASTER
  41. Rosenson, R., Stein, J., & Durrington, P. (2020). Lipoprotein(a). Retrieved from https://www.uptodate.com/contents/lipoprotein-a
  42. Rowland, C. M., Pullinger, C. R., Luke, M. M., Shiffman, D., Green, L., Movsesyan, I., . . . Undas, A. (2014). Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties. Thromb Res, 133(5), 863-867. doi:10.1016/j.thromres.2014.01.024
  43. Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016). Structure, function, and genetics of lipoprotein (a). J Lipid Res, 57(8), 1339-1359. doi:10.1194/jlr.R067314
  44. Scipione, C. A., McAiney, J. T., Simard, D. J., Bazzi, Z. A., Gemin, M., Romagnuolo, R., . . . Koschinsky, M. L. (2017). Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a). J Thromb Haemost, 15(9), 1834-1844. doi:10.1111/jth.13759
  45. Shiffman, D., Slawsky, K., Fusfeld, L., Devlin, J. J., & Goss, T. F. (2012). Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease. Clin Ther, 34(6), 1387-1394. doi:10.1016/j.clinthera.2012.04.004
  46. Steyrer, E., Durovic, S., Frank, S., Giessauf, W., Burger, A., Dieplinger, H., . . . Kostner, G. M. (1994). The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest, 94(6), 2330-2340. doi:10.1172/JCI117598
  47. Tregouet, D. A., Konig, I. R., Erdmann, J., Munteanu, A., Braund, P. S., Hall, A. S., . . . Samani, N. J. (2009). Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet, 41(3), 283-285. doi:10.1038/ng.314
  48. Tsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., . . . Liu, L. (2018). NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol, 71(2), 177-192. doi:10.1016/j.jacc.2017.11.014
  49. Tuten, A., Gungor, Z., Ekmekci, H., Ekmekci, O. B., Kucur, M., Yilmaz, N., . . . Madazli, R. (2019). Relationship between LPA SNPs and inflammatory burden in patients with preeclampsia to address future cardiovascular risk. J Matern Fetal Neonatal Med, 1-9. doi:10.1080/14767058.2019.1622667
  50. Wang, F. M., & Zhang, Y. (2019). High Lipoprotein(a) Level Is Independently Associated with Adverse Clinicopathological Features in Patients with Prostate Cancer. Dis Markers, 2019, 9483935. doi:10.1155/2019/9483935
  51. Wang, H., Hong, C. E., Lewis, J. P., Zhu, Y., Wang, X., Chu, X., . . . Fu, M. (2016). Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis. G3 (Bethesda), 6(11), 3525-3532. doi:10.1534/g3.116.034702
  52. Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019). Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol, 13(3), 374-392. doi:10.1016/j.jacl.2019.04.010
  53. Zekavat, S. M., Ruotsalainen, S., Handsaker, R. E., Alver, M., Bloom, J., Poterba, T., . . . Group, N. T. L. W. (2018). Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. Nat Commun, 9(1), 2606. doi:10.1038/s41467-018-04668-w
  54. Zewinger, S., Kleber, M. E., Tragante, V., McCubrey, R. O., Schmidt, A. F., Direk, K., . . . Speer, T. (2017). Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol, 5(7), 534-543. doi:10.1016/S2213-8587(17)30096-7

Coding Section

Codes Number Description
CPT   No specific code (see Policy Guidelines)
ICD-9-CM Diagnosis   Investigational for all relevant diagnoses
ICD-10-CM (effective 10/01/15) E78.00-E78.9  Disorders of lipoprotein metabolism and other lipidemias
  E88.81 Metabolic syndrome
  I20.0-I25.9 Ischemic heart diseases
ICD-10-PCS (effective 10/01/15)   Not applicable. ICD-10-PCS codes are only used for inpatient services. There are no ICD procedure codes for laboratory tests.

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive. 

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies and accredited national guidelines.

"Current Procedural Terminology© American Medical Association.  All Rights Reserved" 

History From 2014 Forward     

01/01/2021 

Annual review, no change to policy intent. Updating description, rationale and references. 

01/01/2020 

Annual review, no change to policy intent. 

01/09/2019 

Annual review, updating title for clarity. Adding investigational statement regarding Lp(a). Updating ICD coding. 

01/25/2018 

Annual review, no change to policy intent. Updating background, description, guidelines (with coding), rationale and references.. 

04/26/2017 

Annual review, no change to policy intent. Updated to laboratory category and review date. 

05/11/2016 

Annual review, no change to policy intent. Updating background, description, rationale and references. 

06/01/2015 

Annual review, no change to policy intent. Updating background, description, rationale and references. Adding FDA status, coding and guidelines. 

05/26/2014

Annual review. Updated rationale and references. Added related policies. No change to policy intent. 

 


Go Back